Marn C S, Andrews J C, Francis I R, Hollett M D, Walker S C, Ensminger W D
Department of Diagnostic Radiology, University of Michigan Hospital, Ann Arbor 48109-0030.
Radiology. 1993 Apr;187(1):125-8. doi: 10.1148/radiology.187.1.8451398.
The serial contrast material-enhanced computed tomographic scans of 23 patients treated with intraarterial yttrium-90 microspheres as therapy for hepatic metastatic disease were reviewed for evidence of parenchymal changes in the liver in areas not involved with tumor. Irregular low-attenuation geographic areas that developed in the hepatic parenchyma after therapy were graded as mild, moderate, or severe and were evident in 12 of 23 patients. In nine cases of mild to moderate changes in the hepatic parenchyma, the abnormality was either focal or asymmetric. In all three patients receiving the highest dose (15,000 cGy), severe diffuse parenchymal changes were seen in all hepatic segments. In the remaining 11 patients, no parenchymal changes were seen. The most pronounced changes were seen at 8 weeks after therapy and were partially or completely reversible at 16-24 weeks. All patients had minimal or no change in liver function and no clinical sequelae attributable to liver injury.
回顾了23例接受动脉内钇-90微球治疗肝转移性疾病患者的系列对比剂增强计算机断层扫描,以寻找肝脏未受累区域实质变化的证据。治疗后肝脏实质内出现的不规则低密度区域被分为轻度、中度或重度,23例患者中有12例出现这种情况。在9例肝实质轻度至中度变化的病例中,异常表现为局灶性或不对称性。在接受最高剂量(15,000 cGy)的所有3例患者中,所有肝段均出现严重弥漫性实质变化。其余11例患者未观察到实质变化。最明显的变化在治疗后8周出现,在16 - 24周时部分或完全可逆。所有患者肝功能变化极小或无变化,且无肝损伤导致的临床后遗症。